Cleanic Plus tissues is a variant for women with bacterial or fungal infections. They effectively clean intimate zone. Special formula with prebiotic, Dermosoft® Decalact, and cranberry extract helps with protection from both bacterial and fungal infections. Delicate and soft tissue ensures comfortable use.
Cleanic tissues are dermatologically and gynaecologically tested - women can be sure it's a high-quality product. New, smaller package works perfectly in any situation - at work, at home, during on a journey. Cleanic intimate hygiene tissues are biodegradable and fully flushable - they can be disposed in a toilet.
Aqua, Glycerine, Betaine, Vaccinium Mactocarpon Fruit Extract, Undecylenamidopropyl Betaine, Bisabolol, Panthenol, Apha-Glucan, Oligosaccharide, Inulin, Trithyl Citrate, Polyglyceryl-4 Caprate, Sodium Caproyl/Lauroyl Lactylate, Phenoxyethanol, Ethylhexyglycerin, Sodium Benzoate, Potassium Sorbate, Parfum, Lactic Acid.
It's an ingredient that restores and helps with maintaining correct intimate zone pH. Additionally, it helps to restore natural bacterial flora of the intimate zone, and has anti-inflammatory and anti-fungal properties.
It's a natural active ingredient, which contains a lot of vitamin C, vitamins of the B group, micro- and macro-elements, and mineral salts. Due to its contents, it effectively increases skin resistance to external factors and supports epidermis regeneration. Cranberry extract antibacterial properties help with skin diseases, and additionally nourish it and ensure optimal moisture level.
It's a natural active ingredient with antibacterial properties. It effectively eliminates bacteria and microbes responsible for unpleasant odour. It counteracts skin infections and diseases, e.g. mycosis. Additionally it soothes irritation, moisturises, and supports epidermis regeneration.Main advantages: - effective refreshing and urine smell neutralising formula - flushable and 100% biodegradable tissue - small, discreet package
The manufacturer of the Cleanic
brand is Harper Hygienics
investor relations on